Excretion of tacrolimus glucuronides in human bile

被引:13
作者
Firdaous, I
Verbeeck, RK
Hassoun, A
Langrehr, JM
Wallemacq, PE
机构
[1] UNIV CATHOLIQUE LOUVAIN,HOSP ST LUC,DEPT CLIN CHEM,B-1200 BRUSSELS,BELGIUM
[2] UNIV CATHOLIQUE LOUVAIN,SCH PHARM,B-1200 BRUSSELS,BELGIUM
[3] FREE UNIV BERLIN,HOSP RUDOLF VIRCHOW,DEPT SURG,D-1000 BERLIN,GERMANY
关键词
in vivo glucuronidation; tacrolimus; therapeutic drug monitoring; transplantation;
D O I
10.1007/BF03189810
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tacrolimus is extensively metabolized by the cytochrome P-450 system. Hepatic metabolic phase I reactions of tacrolimus include mainly demethylation and/or hydroxylation. No valid data have been published on phase II pathways (glucuronide or sulfo-conjugation). In order to investigate these pathways, different beta-glucuronidase/sulfatase enzyme preparations were used to hydrolyse the conjugates potentially present in human bile extracts. Two analytical methods were used: a non-specific method, MEIA, and a specific combined HPLC/MEIA method. The influence of the extraction pH was investigated. After P-glucuronidase hydrolysis and extraction at pH 5, tacrolimus concentrations, obtained either from HPLC-MEIA or MEIA, always appeared significantly higher, suggesting the presence of glucuronides in the bile. When the extraction was performed at pH 1.5, only the HPLC-MEIA concentrations appeared higher after hydrolysis. MEIA concentrations obtained before and after hydrolysis were similar. These data are consistent with the fact that glucuronides are extracted at pH 1.5 but not at pH 5 and suggest first that, without hydrolysis, the extracted glucuronides are separated from the tacrolimus fraction in the HPLC-MEIA procedure, and second, that the glucuronides are cross-detected by the monoclonal antibody in the immunoassay. From these data, it is concluded that clues have been found, suggesting the presence in human bile of tacrolimus glucuronides, which cross-react with the monoclonal antibody, provided they are extracted in the sample tested.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 14 条
[1]  
CHRISTIANS U, 1991, TRANSPLANT P, V23, P940
[2]  
CHRISTIANS U, 1991, TRANSPLANT P, V23, P2741
[3]  
FIRDAOUS I, 1995, CLIN CHEM, V41, P1292
[4]  
GEORGE A, 1988, DRUG METAB DISPOS, V16, P30
[5]  
IWASAKI K, 1995, DRUG METAB DISPOS, V23, P28
[6]   GLUCURONIDATION OF DRUGS - A REEVALUATION OF THE PHARMACOLOGICAL SIGNIFICANCE OF THE CONJUGATES AND MODULATING FACTORS [J].
KROEMER, HK ;
KLOTZ, U .
CLINICAL PHARMACOKINETICS, 1992, 23 (04) :292-310
[7]  
LHOEST G, 1993, DRUG METAB DISPOS, V21, P850
[8]   CHARACTERIZATION OF PARACETAMOL UDP-GLUCURONOSYLTRANSFERASE ACTIVITY IN HUMAN LIVER-MICROSOMES [J].
MINERS, JO ;
LILLYWHITE, KJ ;
YOOVATHAWORN, K ;
PONGMARUTAI, M ;
BIRKETT, DJ .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (03) :595-600
[9]  
SATTLER M, 1992, DRUG METAB DISPOS, V20, P753
[10]  
SHAH IA, 1991, TRANSPLANT P, V23, P2783